List of Prolensa drug patents

Prolensa is owned by Bausch And Lomb.

Prolensa contains Bromfenac Sodium.

Prolensa has a total of 9 drug patents out of which 0 drug patents have expired.

Prolensa was authorised for market use on 05 April, 2013.

Prolensa is available in solution/drops;ophthalmic dosage forms.

Prolensa can be used as treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery, method of treating ocular inflammation; method of treatment to alleviate inflammation of the eye; method of treating ocular inflammation.

The generics of Prolensa are possible to be released after 11 November, 2033.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8129431 BAUSCH AND LOMB Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
Sep, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8927606 BAUSCH AND LOMB Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
Jan, 2024

(11 months from now)

US9561277 BAUSCH AND LOMB Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
Jan, 2024

(11 months from now)

US9144609 BAUSCH AND LOMB Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
Jan, 2024

(11 months from now)

US8669290 BAUSCH AND LOMB Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
Jan, 2024

(11 months from now)

US8754131 BAUSCH AND LOMB Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
Jan, 2024

(11 months from now)

US8871813 BAUSCH AND LOMB Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
Jan, 2024

(11 months from now)

US10085958 BAUSCH AND LOMB Bromfenac bioavailability
Nov, 2032

(9 years from now)

US9517220 BAUSCH AND LOMB Bromfenac bioavailability
Nov, 2033

(10 years from now)

Drugs and Companies using BROMFENAC SODIUM ingredient

Market Authorisation Date: 05 April, 2013

Treatment: Method of treating ocular inflammation; Method of treatment to alleviate inflammation of the eye; Treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of PROLENSA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic